Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9615474 | 0.83 | THRB (0.60) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL2909701 | 0.82 | ALDH1A1 (0.59) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL2174959 | 0.80 | TSHR (0.52) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL12643182 | 0.78 | CYP1A2 (0.47) | CYP1A2GAAMGAMSIMGAM2 | |
| Ethyl Pyruvate SCHEMBL1331224 | 0.78 | — | — | |
| Ethyl Pyruvate SCHEMBL25538 | 0.78 | — | — | |
| Ethyl Pyruvate SCHEMBL28156490 | 0.78 | GLO1 (0.61) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL10924595 | 0.77 | GAA (0.50) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL4444616 | 0.77 | GAA (0.50) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL4444617 | 0.77 | GAA (0.50) | CYP1A2GAAMGAMSIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1494659-B1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMIDE AND LACTIC ACID OR A LACTIC ACID SALT | CRITICAL THERAPEUTICS INC (US) | 2005-10-12 | — | — | EP | claimed |
| EP-1494659-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMIDE AND LACTIC ACID OR A LACTIC ACID SALT | Critical Therapeutics, Inc. (US) | 2005-01-12 | — | — | EP | claimed |
| US-20030232884-A1 | New pharmaceutical formulation | CRITICAL THERAPEUTICS, INC. | 2003-12-18 | — | — | US | claimed |
| WO-2003088955-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMINE AND LACTIC ACID OR A LACTIC ACID SALT | CRITICAL THERAPEUTICS, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| EP-2493467-B1 | COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS | HILLS PET NUTRITION INC (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2519115-B1 | COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF | HILLS PET NUTRITION INC (US) | 2017-02-15 | — | — | EP | disclosed |
| US-9173422-B2 | Compositions including pyruvate for companion animals and methods of use thereof | HILL'S PET NUTRITION, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9011900-B2 | Compositions including pyruvate for companion animals and methods of use thereof | HILL'S PET NUTRITION, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8999375-B2 | Compositions including pyruvate for companion animals and methods of use thereof | HILL'S PET NUTRITION, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20120309828-A1 | COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF | HILL'S PET NUTRITION, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309829-A1 | COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF | HILL'S PET NUTRITION, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120289598-A1 | COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF | HILL'S PET NUTRITION, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| EP-2493467-A1 | COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF | Hill's Pet Nutrition, Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011090676-A1 | COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF | HILL'S PET NUTRITION, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011082081-A1 | COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF | HILL'S PET NUTRITION, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011082080-A1 | COMPOSITIONS INCLUDING PYRUVATE FOR COMPANION ANIMALS AND METHODS OF USE THEREOF | HILL'S PET NUTRITION, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| EP-1494659-B1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMIDE AND LACTIC ACID OR A LACTIC ACID SALT | CRITICAL THERAPEUTICS INC (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1494659-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMIDE AND LACTIC ACID OR A LACTIC ACID SALT | Critical Therapeutics, Inc. (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20030232884-A1 | New pharmaceutical formulation | CRITICAL THERAPEUTICS, INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003088955-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMINE AND LACTIC ACID OR A LACTIC ACID SALT | CRITICAL THERAPEUTICS, INC. (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232884-A1 | New pharmaceutical formulation | LIPA, CEL, LDHA | CYP1A2 2159/4885GAA 82/4885MGAM 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.